Eicosapentaenoic Free Fatty Acid and Fecal Calprotectin in Inflammatory Bowel Diseases

Inclusion Criteria: * Age ranged between18 and 80 years. * Patients with Ulcerative Colitis (diagnosed on the base of clinic, endoscopic and histologic criteria) in clinical remission (SCCAI = 0) from at least 3 months and in stable therapy (without therapeutic modifications in the three previous months) with 5-ASA, immunomodulators and/or biologics. * Patients affected by Crohn's Disease (diagnosed on the base of clinic, endoscopic and histologic criteria) ) in clinical remission (CDAI \< 150) from at least 3 months and in stable therapy (without therapeutic modifications in the three previous months) with 5-ASA, immunomodulators and/or biologics. * Fecal calprotectin at baseline \> 150 μg/g. Exclusion Criteria: * Patients affected by Ulcerative Colitis and Crohn's Disease respectively with a SCCAI ≥ 1 and a CDAI ≥150. * Patients on steroid therapy. * Patients in therapy wih warfarin or other anticoagulants. * Known or supposed ipersensitivity to eicosapentaenoic acid/omega 3. * Women in fertile age which refuse to use contracceptives specified in the study (oral contraception, IUD) and breastfeed women. * Patients with severe clinical conditions which the investigator consider to controindicate patient partecipation at the study. * Therapy modifications and/or assumption of sperimental therapies within three months before the study inclusion. * Patients unable to follow protocol procedures and to sign the informate consent.